Roivant Sciences, a three-year-old, Basel, Switzerland-based company aiming to one day be a giant holding company for dozens of independent biopharmaceutical companies, has raised $1.1 billion in equity led by the SoftBank Vision Fund — making it the latest in a string of enormous bets by SoftBank, and putting the young outfit more squarely on the radar of the tech world. Read More
Source: TechCrunch.fundings-exits
